In an exclusive conversation with Fortune India, the executive chairperson of Biocon says India should immediately start mixing and matching existing vaccines to accelerate the vaccination drive.
India’s vaccine giant faces the huge social responsibility of supply into the domestic market and a contractual demand for export of vaccines to foreign countries.
The central bank unveils liquidity facility of ₹50,000 crore for access to emergency health services, and ₹10,000 crore for small finance banks’ on-lending, among a slew of measures to fight Covid-19.
In a big move, India has opened up Covid-19 vaccinations for all adults. However, the country is beset by severe vaccine shortage and other challenges. Will increasing the demand base work?
Experts say that while ramping up of vaccination could give some relief to multiplexes, the ongoing staggered lockdown in many states poses a bigger threat.
The country’s daily requirement is over 10 million doses against the production of 2.9 million. The Sputnik V vaccine, which got the nod on Monday, will help bridge the gap, albeit marginally.
One of the issues with vaccine development is the enormous time required to produce one. The Covid-19 vaccine has shown the process can be expedited. But can the process be made even more faster?
India’s pharma industry is reimagining itself. This is not just borne out of the necessities brought forth by the pandemic, but is a blueprint to thrive and to succeed in this new world.
Aided by strong demand recovery, credit ratio rebounds to 1.33 in H2FY21, from 0.54 in H1FY21. GDP could grow at 11% in FY22, but the resurgence in Covid-19 cases is a key downside risk, says CRISIL.
